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Abstract 
Genetic polymorphisms of the genes encoding for the xenobiotic metabolizing enzymes result in 
individual variations in the efficiency of detoxification of environmental carcinogens, and have been 
extensively associated with variable risk for lung neoplasms in different ethnic and environmental 
backgrounds. In this study, using PCR-RFLP based assays, we investigated the distribution of genetic 
polymorphisms in CYP1A1, GSTM1 and GSTT1 genes in Greek lung cancer patients (N=122) and healthy 
controls (N=178). The frequency of CYP1A1 m1 homozygous genotype was 0.04 in patients and 0.02 in 
controls (detected in 4.10% of patients and in 1.69% of controls, respectively), that of GSTM1 null 
genotype was 0.52 in patients and 0.54 in controls, whereas those of GSTT1 null genotype was 0.17 and 
0.11, in patients and controls, respectively. The GSTM1 null genotype was more frequent in 
adenocarcinoma, as well as in lung cancer patients with history of chronic obstructive pulmonary disease 
(COPD). The GSTT1 null genotype correlated with advanced age of the patients at the time of diagnosis. 
Three combinations of rare genotypes - in subjects carrying simultaneously deviations from the common 
genotype in more than one gene - were over-represented in lung cancer patients, compared to control 
population, and were furthermore significantly associated with history of heavy tobacco consumption in 
lung cancer patients. The results imply involvement of specific genotype combinations of CYP1A1, 
GSTM1 and GSTT1 alleles in the development of lung cancer in heavy smokers. 
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Abstract. Genetic polymorphisms of the genes encoding for
the xenobiotic metabolizing enzymes result in individual
variations in the efficiency of detoxification of environmental
carcinogens, and have been extensively associated with variable
risk for lung neoplasms in different ethnic and environmental
backgrounds. In this study, using PCR-RFLP based assays,
we investigated the distribution of genetic polymorphisms
in CYP1A1, GSTM1 and GSTT1 genes in Greek lung cancer
patients (N=122) and healthy controls (N=178). The frequency
of CYP1A1 m1 homozygous genotype was 0.04 in patients and
0.02 in controls (detected in 4.10% of patients and in 1.69%
of controls, respectively), that of GSTM1 null genotype was
0.52 in patients and 0.54 in controls, whereas those of GSTT1
null genotype was 0.17 and 0.11, in patients and controls,
respectively. The GSTM1 null genotype was more frequent in
adenocarcinoma, as well as in lung cancer patients with history
of chronic obstructive pulmonary disease (COPD). The GSTT1
null genotype correlated with advanced age of the patients at
the time of diagnosis. Three combinations of rare genotypes - in
subjects carrying simultaneously deviations from the common
genotype in more than one gene - were over-represented in
lung cancer patients, compared to control population, and were
furthermore significantly associated with history of heavy
tobacco consumption in lung cancer patients. The results imply
involvement of specific genotype combinations of CYP1A1,
GSTM1 and GSTT1 alleles in the development of lung cancer
in heavy smokers.
Introduction
Incidence and mortality from lung cancer in Greece have
increased significantly during the last decades (1). Changes
in environmental factors and in lifestyle, mainly in smoking
habits, have been associated with increased lung cancer risk
(2). The environment-gene interaction for cancer development
is largely attributed to the action of xenobiotic metabolizing
enzymes (XME). Individual differences in the bioactivation
of procarcinogens and in detoxification of carcinogens,
arising from alterations in XME genes, may explain varying
susceptibilities to lung cancer (3,4).
CYP1A1 enzyme is involved in the activation of
benzo(a)pyrene, other polycyclic aromatic hydrocarbons
(PAHs) and aromatic amines, all of them major classes of
tobacco procarcinogens. The m1 polymorphism in the 3' non-
coding region (3'-UTR) of the CYP1A1 gene arises from a
T➝ C transition, thus the m1 allele bears a MspI cleavage site, in
contrast with the wild-type variant (5). The CYP1A1 m1 poly-
morphism has been associated with alterations in regulation
and transcript half-life, which result in elevated induction of the
enzyme, and thus, increased levels of activated intermediates
(6). The m1 homozygous genotype has been associated with
increased risk of lung cancer among Asian populations (7,8),
but this association has not been established in Caucasian or
Afro-American populations (9,10).
The cytosolic glutathione S-transferase (GST) enzyme
family consists of at least 20 isoenzymes. GSTM1 is
involved in degradation of active metabolites of polycyclic
aromatic hydrocarbons (PAH) (11), whereas GSTT1
participates in detoxification of small hydrocarbons of
tobacco smoke (such as monohalomethanes and ethylene
oxide) (12). Lack of enzyme detoxification activity is due to
inherited complete deletion of the respective genes (13,14).
Ethnic variations have been reported for polymorphisms of
GST genes, but generally the homozygous GSTM1 null
genotype is more frequent than the GSTT1 null genotype
(15,16). Homozygous deletions of GST genes, alone or in
combinations, have been associated with increased risk of
lung cancer among Caucasians (17,18).
In this study, we investigated the distribution of geno-
types of CYP1A1, GSTM1 and GSTT1, as well as their
combinations, among Greek lung cancer patients and healthy
controls. Furthermore, we tested for associations of the poly-
morphisms with the epidemiologic parameters, exposure to
established risk factors for lung cancer, and the clinico-
pathological data of cancer cases, in order to evaluate the role
of polymorphisms of those XME genes in lung cancer
susceptibility.
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Materials and methods
Specimens and data collection. During the 18-month study
period (April 2001-September 2002) peripheral blood was
collected from 122 Greek patients (105 male and 17 female),
newly diagnosed with lung cancer, as well as from 178 Greek
healthy controls (148 male and 30 female), at the ‘Sotiria’
University Hospital, Athens, Greece. Samples were stored at
4˚C. Histological type and degree of differentiation of all
cancer cases was assessed by histological examination of
surgery or bronchoscopy specimen. All non-small cell lung
cancer cases were staged on initial diagnosis according to the
TNM International Staging System, while small cell lung
cancer cases were grouped as limited-stage or extensive-stage
disease (19). Furthermore, data on patients were collected
upon the time of blood sampling, through the completion of a
questionnaire. This included sociodemographic characteristics -
gender, age, lifetime occupational history (including exposure
to known carcinogens, such as asbestos, aniline, ortho-
toluidine, etc.), area of origin, residence setting (rural-urban),
family history of cancer in first-degree relatives - as well as
smoking status (expressed as pack/years), medication history,
and the pre-existence of respiratory disease (i.e. COPD) or
history of other lung disease (i.e. pulmonary fibrosis, tuber-
culosis). The survival data for the study period, as well as the
treatment modalities were available for all patients in the
study. Patients gave written informed consent prior to blood
and data collection. All control blood samples were derived
from apparently healthy individuals, without previous history
of any cancer type, and without family history of lung cancer
among first-degree relatives. The ethics Committee of the
University of Crete approved this study.
DNA extraction. Genomic DNA was extracted from whole
blood using proteinase K, followed by phenol extraction and
ethanol precipitation according to standard procedures (20).
DNA was resuspended in 50 µl TE buffer (10 mM Tris-HCl,
1 mM EDTA, pH 8.0). Working stocks were prepared by
10-fold dilution in double distilled H2O.
Polymerase chain reaction (PCR) and restriction fragment
length polymorphism (RFLP). PCR assays were performed
by introducing 100 ng of genomic DNA in a PCR reaction
mixture containing 1X PCR buffer, 200 µM dNTPs, 2.0 mM
MgCl2 and 0.35 U Taq DNA polymerase (Life Technologies
Ltd., UK) to a 15 µl total reaction volume. For the CYP1A1
polymorphism, a 340 bp DNA fragment was amplified by
PCR with primers (used to a final concentration of 0.3 µM)
and amplification parameters as previously described (21).
RFLPs were performed by complete digestion of the PCR
product with MspI. Wild-type (wt) genotype was characterized
by an approximately 340 bp fragment, while the presence
of 134, 206 and 340 bp fragments signified heterozygosity
(wt/m1 genotype), and the homozygous m1 genotype was
recorded when only the 134 and 206 fragments were
observed. The oligonucleotide primer sequences (used to a
final concentration of 0.3 µM) for the co-amplification of
either GSTM1 or GSTT1 with ß-globin as an internal positive
control, as well as the PCR conditions have been previously
described (22).
Electrophoresis. PCR and RFLP products were analysed by
8% polyacrylamide gel electrophoresis (29:1 ratio acrylamide/
bis-acrylamide) and silver stained. Gels were scanned on an
Agfa SnapScan 1212u (Agfa-Gevaert N.V., Belgium).
Statistical analysis. To analyze the polymorphism data against
the risk factors and the clinicopathological parameters, Chi-
square test with estimation of odds ratio or Fisher's exact
test were used, as appropriate, for comparison of categorical
variables, while one-way ANOVA was used for comparison
of continuous variables. In addition, correlation coefficient
analysis and non-parametric procedures were applied, where
appropriate. Statistical significance was accepted for p-values
of <0.05. Analysis was performed using the SPSS (version
11.0) software (SPSS Inc., USA).
Results
The present study involved 122 lung cancer patients and 178
apparently healthy controls, all of them being of Greek
ethnicity. The main characteristics of the patient study group
are shown in Table I. Additionally, among smoker patients
the mean cigarette exposure (estimated in pack/years) was
65.06 (median 60, SD 33.67, range 10-160). Sixteen patients
had a positive history of lung cancer among first-degree
relatives. Fifty-eight and 64 patients lived in urban and rural
settings, respectively. Thirty-nine patients declared definitive
occupational exposure to known carcinogens, while 48 patients
had no history of occupational risk exposure and 19 patients
declared probable exposure for a limited period of time. For
the remaining 16 patients, detailed occupational history could
not be recalled with accuracy. Chemotherapy was offered to
67 patients, 30 patients underwent operative treatment, while
for 36 patients the treatment schedule contained radiotherapy.
Twenty-nine patients had died at the end of the study period.
The control group consisted of 148 males and 30 females.
Gender distrubution did not differ between cases and controls
(Pearson ¯2 p=0.494), the mean age, however, of controls was
slightly lower than that of the patient group (58.81 vs 64.64,
respectively, one-way ANOVA p=0.004).
The PCR-RFLP analysis for the CYP1A1 polymorphism
is presented in Fig. 1. The multiplex PCR analysis for the
GSTM1 and GSTT1 polymorphisms, with ß-globin as positive
internal control, are shown in Figs. 2 and 3. The distribution
of individual genotypes for CYP1A1, GSTM1 and GSTT1 in
the study population is shown in Table II. The frequency of
homozygous individuals for m1 CYP1A1 polymorphism was
0.04 in lung cancer cases and 0.02 in controls (odds ratio:
0.40, 95% CIs: 0.09-1.71). The frequency of GSTM1 null(-)
genotype was 0.52 in cases and 0.54 in controls (OR: 0.91,
95% CIs: 0.58-1.45), while that of GSTT1 null(-) genotype was
0.17 and 0.11 in cases and controls, respectively (OR: 1.64,
95% CIs: 0.85-3.18). Statistical analysis did not reveal any
significant differences in genotype prevalence between the two
study groups (patients, controls), for all three genes examined.
The CYP1A1 m1 allele was encountered more frequently
in adenocarcinoma (10 out of 30 cases) compared to squamous
cell carcinoma (2 out of 22 cases), and the difference
marginally failed to reach statistical significance (Fisher's
exact test, p=0.051, OR: 5.00, 95% CIs: 0.97-25.77). On the
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other hand, the GSTM1 null genotype was over represented
in adenocarcinoma (21 out of 30 cases) compared to other
histological types (p=0.046, OR: 2.67, 95% CIs: 1.01-7.08)
(Table III). Furthermore, the GSTM1 null genotype was
encountered significantly more frequently in lung cancer
patients with history of COPD compared to patients with
history of other chronic lung disease (Fisher's exact test,
p=0.023, OR: 8.00, 95% CIs: 1.33-48.18) (Table III). No
association was detected among the genotype frequencies of
the XME genes, when patients with history of COPD were
compared to patients without prior respiratory history. The
GSTT1 null genotype did not correlate with the histological
type of lung cancer. On the contrary, an association was
detected between GSTT1 status and age, among lung cancer
patients: the 21 patients with the GSTT1 null genotype had
significantly higher age than the 101 patients bearing the
gene (mean age 70.1 vs 63.5, one-way ANOVA p=0.002).
The distribution of genotype combinations for the three
genes among the study population is presented in Table II.
Twelve different genotype variations may arise from the
possible combinations of CYP1A1 (homozygous wt,
homozygous m1, heterozygous), GSTM1 (homozygous
deletion or allele present) and GSTM1 (homozygous deletion
or allele present), and 11 out of those were observed in this
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Small cell carcinoma 21 (17.2)
Squamous cell carcinoma 22 (18)
Adenocarcinoma 30 (24.6)
Other (bronchoalveolar, large-cell) 2 (1.7)




Other lung disease 10 (8.2)
(i.e. Tb, bronchiectasis etc.)
Other system disease 44 (36.1)
Lung and other system disease 17 (13.9)
None 30 (24.6)
Smoking status
Current smoker 77 (63.1)
Former smoker 35 (28.7)
Life-long non-smoker 10 (8.2)






Figure 1. Representative examples of CYP1A1 MspI 3'-UTR polymorphism
analysis. M, DNA molecular size standard. Lanes 1 and 7, uncut CYP1A1 PCR
product. Lanes 2 and 3, homozygous wild-type samples; lanes 4 and 5, hetero-
zygous samples (wt/m1). Lane 6, homozygous m1 sample.
Figure 2. Representative examples of multiplex PCR assays for GSTM1 poly-
morphism and ß-globin. M, DNA molecular size standard. Lane 1, ß-globin
(singleplex). Lanes 2-4, GSTM1(+); lanes 5-7, GSTM1(-).
Figure 3. Representative examples of multiplex PCR assays for GSTT1 poly-
morphism and ß-globin. M, DNA molecular size standard. Lane 1, ß-globin
(singleplex). Lanes 2-4, GSTT1(+); lanes 5-7, GSTT1(-).
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Gene allele Frequency Frequency Odds ratio 95% CI
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CYP1A1
Wt 0.73 0.73 1.02 0.61-1.72
wt/m1 0.23 0.25 0.86 0.50-1.47
m1 0.04 0.02 0.40 0.09-1.71
GSTM1
Null 0.52 0.54 0.91 0.58-1.45
Present 0.48 0.46 1.05 0.82-1.34
GSTT1
Null 0.17 0.11 1.64 0.85-3.18




Genotype Lung cancer cases Controls
––––––––––––––––––––––––––– –––––––––––––––––––– ––––––––––––––––––––
CYP1A1 GSTM1 GSTT1 No. cases Frequency No. cases Frequency Odds ratio 95% CI
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Wt + + 33 0.27 52 0.30 0.90 0.52-1.55
wt/m1 + + 12 0.09 21 0.11 0.82 0.36-1.83
m1 + + 2 0.02 2 0.01 1.47 0.15-14.78
Wt - + 42 0.34 62 0.35 0.98 0.59-1.64
wt/m1 - + 10 0.08 20 0.11 0.71 0.30-1.66
m1 - + 2 0.02 1 0.01 2.95 0.21-83.05
Wt + - 7 0.06 5 0.03 2.11 0.58-7.86
wt/m1 + - 5 0.04 2 0.01 3.76 0.64-28.49
m1 + - 0 0.00 0 0.00
Wt - - 7 0.06 11 0.06 0.92 0.31-2.67
wt/m1 - - 1 0.01 2 0.01 0.73 0.03-10.35
m1 - - 1 0.01 0 0.00
Total 122 1.00 178 1.00
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table III. Associations of GSTM1 genotype with histological type, and with past respiratory history of lung cancer patients.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––




Adenocarcinoma 21 9 0.046 2.67 1.01-7.08
Other histological typesa 21 24
History of COPD 14 7 0.023 8.00 1.32-48.18
History of other lung disease 2 8
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aIncluding only definite types (i.e. small cell, squamous). Poorly differentiated cases, as well as NSCLC cases, otherwise non-specified, were
excluded from analysis.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
study. Four combinations occur with high, similar
frequencies in patients and controls, together exceeding 80%
of cases (Table II). The remaining 7 genotypic combinations
are represented in ≤5% each, in both study groups. It is of
note that 3 out of those 7 rare genotypic combinations, that
is CYP1A1(wt/m1)/GSTM1(+)/GSTT1(-), CYP1A1(m1)/
GSTM1(-)/GSTT1(+) and CYP1A1(wt)/ GSTM1(+)/GSTT1(-)
(each including at least one homozygous deletion) had higher
frequencies among patients than among controls, and were
associated with increased risk for lung cancer (odds ratios
3.76, 2.95, and 2.11, respectively), although the differences
did not reach statistic significance, apparently due to the
small size of sample in each category.
Genotype distributions for the XME genes examined in
the present study could not be associated with the smoking
history of the patients (only 10 patients were non-smokers).
However, when smokers were analyzed into quartiles
according to the distribution of our samples, a difference was
detected between patients in the lowest and the highest
smoke consumption quartiles, marginally failing to reach
statistical significance: presence of the three rare genotype
combinations described above was more frequently detected
among current smokers with record of exposure >80 pack/years
(6 cases among 28 patients) than among current smokers
with exposure <40 pack/years (3 cases among 49 patients)
(Fisher's exact test, p=0.053, OR: 4.18, 95% CIs: 0.82-23.68)
(Table IV). No significant associations could be established
between any genotype combinations and histological type,
TNM stage, degree of differentiation, family history, residence
setting, occupational risk history, response to treatment, and
survival (data not shown).
Discussion
In the present study, we examined the genotyping profile for
the CYP1A1, GSTM1, and GSTT1 genes, all involved in the
metabolism of common carcinogens, in a series of Greek
lung cancer patients and healthy controls. Several poly-
morphisms of the genes encoding for these enzymes have
been reported with increased frequency among lung cancer
patients, in different ethnicity and environmental backgrounds
(4,8,9,18,23). It must be emphasized that racial variation
clearly exists in the distribution of polymorphisms of XME
genes (15,16,23). Previously, we determined the frequencies
of XME genes in a series of Greek breast cancer patients,
furthermore identifying frequent transcriptional deregulation
of those genes in breast cancer (24). To the best of our
knowledge, this is the first report on the genotype frequency
of these genes in Greek lung cancer patients. We found
that the frequency of m1 allele of CYP1A1 was 16%, of
GSTM1(-) was 52% and of GSTT1(-) was 17% among lung
cancer patients. Previous studies on Caucasian lung cancer
patients have estimated that frequencies of CYP1A1, GSTM1
and GSTT1 were 14%, 48-54%, and 13-26%, respectively
(17,18,25-27).
In the present study, higher prevalence of the CYP1A1
homozygous MspI genotype was recorded among patients
compared to controls (4.1% vs 1.69%, respectively). This
difference failed to reach statistical significance, apparently
due to the size of the sample. In a recently published pooled
analysis of 22 case-control studies, a clear association between
the CYP1A1 homozygous MspI genotype and lung cancer was
detected in Caucasians (28), confirming the finding of our
study.
In contrast with CYP1A1, data on lung cancer risk attributed
to GSTM1 and GSTT1 genes are less consistent. In the present
study, no association between the allelic frequencies of those
genes and lung cancer risk was observed, which is consistent
with previously reported data (27). In a recent meta-analysis,
marginal correlation between the presence of GSTM1 null
genotype and lung cancer risk was reported, without, however,
evidence of interaction between GSTM1 genotype and tobacco
consumption (17). The frequency of GSTM1 null genotype in
our study was slightly lower in lung cancer patients than in
controls, and interestingly, in a previous study in Caucasians,
GSTM1 homozygous (-) genotype has been correlated with
decreased risk for lung cancer (29).
Perhaps the most interesting finding of the present study
was the detection of three rare genotypic combinations with
higher frequency among lung cancer patients compared to
controls. Lung cancer was associated with those combinations
of rare genotypes stronger than with any individual genotype
in our study, as well as than with any of the genotypic
combinations commonly represented in our study groups.
Although differences did not reach statistical significance,
our results are consistent with previously reported data
(14,15,18). In a previous study on European patients, lack of
association of separate genotypes with lung cancer was in
contrast with increased lung cancer susceptibility in persons
showing concurrent lack of the GSTM1 and GSTT1 genes
(27). A recent meta-analysis on CYP1A1 and GSTM1 genes
among non-smokers with lung cancer gave also similar
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Table IV. Associations of three rarely encountered genotypic combinations of XME genes [CYP1A1(wt/m1)/GSTM1(+)/GSTT1(-),
CYP1A1(m1)/GSTM1(-)/GSTT1(+) and CYP1A1(wt)/GSTM1(+)/GSTT1(-)] with smoking status, among current smokers with lung
cancer.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––




High (>80 pack/years) 6 22 0.053 4.18 0.82-23.68
Low (<40 pack/years) 3 46
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
results (30). It seems, therefore, that rather than the individual
genotypes, which present small if any contribution to the
absolute risk of cancer, the combination of rare XME geno-
types - consisting of accumulated genetic alterations, involving
at least one homozygous deletion of GST genes - should be
considered more appropriate for cancer risk assessment.
Contradictory data on the association between XME geno-
types and lung cancer risk according to smoking status exist
in the literature. In a recent study on Caucasian lung cancer
patients diagnosed before 45 years of age, the association
between CYP1A1 genotype and lung cancer was confined to
never smokers (25). Conversely, in a large meta-analysis where
Caucasian patients were stratified according to duration of
smoking, the increase in the risk of lung cancer was greater
in patients carrying the CYP1A1 m1 genotype, than among
the individuals with the homozygous reference allele (28).
On the other hand, another recent meta-analysis, including
large cohorts of patients, concluded that GSTM1 genotype
is not a modifier of the effect of smoking on lung cancer
risk (17). In the present study, we found the three geno-
typic combinations over-represented in lung cancer patients,
furthermore correlated with smoke exposure, the difference
between heavy (exposure >80 pack/years) and light smokers
(exposure <40 pack/years) marginally failing to reach statistical
significance, obviously due to the small number of cases in
each group. This result is consistent with reports from two
previous studies on GST genes, using exposure cut-off of
30 pack/years and 35 pack/years, respectively (18,31). In all
studies, however, the relatively small number of patients with
combinations of rare genotypes, as well as of light smokers,
limits the validity of the estimates. As more studies on the
role of XME genes on lung cancer development become
available, future larger meta-analyses are expected to elucidate
the relationship between specific genotypes of those genes
and tobacco exposure.
In the present study, patients with the GSTT1 null genotype
were diagnosed with lung cancer at significantly older age
than patients bearing the wild-type allele. Although data on
association of XME gene polymorphisms and age are limited,
it has recently been reported that lung cancer patients younger
than 45 years exhibit more frequently the GSTT1 null geno-
type, as well as the CYP1A1 variant allele, compared to age-
matched controls (25).
Presence of CYP1A1 m1 allele in our study was negatively
associated with squamous cell carcinoma compared to adeno-
carcinoma, while the presence of GSTM1 null genotype
correlated with adenocarcinoma. Although these results
appear in discordance with previously reported data (32,33),
it seems that a definite association between polymorphisms
of XME genes and histological type of lung cancer cannot be
established: in two recently published meta-analyses involving
large number of cases the association between the homo-
zygous CYP1A1 m1 variant and lung cancer was equally strong
for squamous cell carcinomas and adenocarcinomas among
Caucasians (28), while no correlation between GSTM1 null
genotype and histological type of lung cancer could be
established (17). It seems therefore that susceptibility to the
effect of carcinogens, arising from polymorphisms in XME
genes, shows no predilection for any histological type of lung
cancer.
An interesting finding of the present study was the
significant association between the GSTM1 null genotype
and history of COPD in lung cancer patients, compared to
patients with history of other lung disease. The association
between GSTM1 gene and COPD has been reported in the
past in several populations, including cohorts of Caucasian
patients (34,35). The connection between GSTM1 gene and
COPD should be considered on the basis that both lung
cancer and COPD have a causative relationship with smoke
exposure. This hypothesis was hard to test in the present
study, as only 10 lung cancer patients were non-smokers,
nevertheless, it is supported by the lack of association between
the genotypes examined when lung cancer patients with pre-
existing COPD were compared to patients with free respiratory
history. It is of note that, in contrast with GSTM1 gene, no
associations between COPD and either CYP1A1, or GSTT1
exist so far in the literature. Therefore, the difference in
frequency of deletions of GSTM1 gene between COPD patients
and patients with other previous respiratory disease could
imply the existence of different pathogenetic mechanisms for
lung cancer development.
In the present study, no association between XME geno-
types and other clinicoepidemiological parameters of lung
cancer cases could be established. This result is in accordance
with the limited data existing so far in the literature. In one
Northern European study, no associations between CYP1A1
gene polymorphisms and family history could be revealed
(36). Furthermore, a meta-analysis on asbestos exposure in
relation to GSTM1 and GSTT1 polymorphisms on Caucasians
could not support the hypothesis that the risk of lung cancer
after asbestos exposure differs according to those genotypes
(37). In another study, performed on an Asian population,
NSCLC patients with at least one CYP1A1 m1 allele (and in
particular smokers and those with advanced disease) were
associated with a shortened survival compared to the wild-
type homozygous patients, and this effect was enhanced
when the CYP1A1 genotype was combined with the GSTM1
null genotype (38). The failure of the present study to establish
any correlations between XME genes and survival or response
to therapy could be attributed to the short follow-up period,
as well as the multiple treatment modalities used, moreover
lung cancer is a malignancy with poor overall prognosis if
not diagnosed early.
In conclusion, we studied the genotyping profile of XME
genes in a series of Greek lung cancer patients and healthy
controls. Homozygous CYP1A1 m1 genotype and GSTT1
homozygous deletion were more frequent in patients than in
controls, however, no definite associations between the
risk for lung cancer and any individual genotype could be
established. It is rather the combination of rare genotypes -
due to accumulated deviations from the common XME
genotypes - that tends to correlate with lung cancer, mainly
in association with high tobacco consumption. These findings
did not reach statistical power in the present study; though
results from recently published meta-analyses are also
consistent with this hypothesis. Combined rare XME geno-
types in patients with previous history of COPD, as well as
differences between lung cancer histological types, may
account for involvement of these genes in the pathogenesis of
distinct lung malignancies. As data on XME genes become
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increasingly available, larger molecular epidemiology studies
are expected to provide further insight into the role of XME
genes in lung carcinogenesis.
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